España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Eli Lilly
LLY
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$785.41
18.81
2.45%
At close: -
$785.10
-0.31
-0.04%
After Hours: Jan 24, 6:42 PM EDT
Get Report
Comment
Q4 2024 Earnings in 11 days from now on Thu Feb 6th, before the market open
Eli Lilly (LLY) Forecast
News
Earnings
Eli Lilly (LLY) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Eli Lilly (NYSE:LLY) Stock
Eli Lilly Stock (NYSE: LLY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, January 22, 2025
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
Kaustubh Bagalkote
Tuesday, January 21, 2025
Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound
Mark Putrino
Sunday, January 19, 2025
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Lekha Gupta
Friday, January 17, 2025
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Anthony Noto
How Is The Market Feeling About Eli Lilly?
Benzinga Insights
'Ozempic Is In The Next Round Of Medicare Dru...
Benzinga Newsdesk
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
Vandana Singh
Thursday, January 16, 2025
U.S. FDA Chief Califf Says Current Regulation...
Benzinga Newsdesk
Eli Lilly's Options: A Look at What the Big Money is Thinking
Benzinga Insights
Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today
Benzinga Insights
Wednesday, January 15, 2025
Eli Lilly Announces The FDA Has Approved Omvo...
Benzinga Newsdesk
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall
Vandana Singh
Microsoft, Applied Digital, Rigetti Computing, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Benzinga Neuro
Tuesday, January 14, 2025
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Eli Lilly Tumbles: What's Driving Markets Tuesday? (CORRECTED)
Piero Cingari
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Vandana Singh
Eli Lily shares are trading lower after the c...
Benzinga Newsdesk
Eli Lilly Expects 2024 Revenue of $45.0B, Abo...
Benzinga Newsdesk
Monday, January 13, 2025
'Lilly Asks Biden Administration to Pause Dru...
Benzinga Newsdesk
'Lilly Sees New Weight-Loss Pill Approval in ...
Benzinga Newsdesk
Eli Lilly Scoops Up Scorpion Therapeutics' Early-Stage Cancer Program For $2.5 Billion
Vandana Singh
Eli Lilly To Acquire Scorpion Therapeutics' N...
Benzinga Newsdesk
Friday, January 10, 2025
"Eli Lilly In Advanced Talks To Buy U.S. Canc...
Benzinga Newsdesk
On Thursday, Alchemab Therapeutics Entered A ...
Benzinga Newsdesk
Thursday, January 09, 2025
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Vandana Singh
Medicare To Cover Eli Lilly's Weight Loss Drug Zepbound For Obstructive Sleep Apnea Treatment
Vandana Singh
Wednesday, January 08, 2025
'Medicare Can Now Cover Eli Lilly's Zepbound ...
Benzinga Newsdesk
Tuesday, January 07, 2025
Eli Lilly's Options: A Look at What the Big Money is Thinking
Benzinga Insights
Monday, January 06, 2025
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
Vandana Singh
Israel Englander's Millennium Management Dumps Nvidia, Loads Up On Broadcom — Here's What The $70 Billion Hedge Fund Sees
Kaustubh Bagalkote
Friday, January 03, 2025
Smart Money Is Betting Big In LLY Options
Benzinga Insights
Jim Cramer Says Lazard Is 'Really Inexpensive,' Recommends Buying This Tech Stock
Avi Kapoor
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
Vandana Singh
Thursday, January 02, 2025
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Vandana Singh
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Vandana Singh
Wednesday, January 01, 2025
$100 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today
Benzinga Insights
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In December 2024 — Where Do Tesla, Nvidia, Quantum Computing Stock Rank?
Chris Katje
Tuesday, December 31, 2024
Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday
Chris Katje
Eli Lilly Unusual Options Activity
Benzinga Insights
Saturday, December 28, 2024
Elon Musk Admits To Using Weight Loss Medication Criticized By RFK Jr, Says He Prefers Mounjaro Over Miracle Drug Ozempic
Anan Ashraf
Thursday, December 26, 2024
Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?
Chris Katje
Monday, December 23, 2024
Ely Lilly shares are trading higher after the...
Benzinga Newsdesk
Eli Lilly Stock Is Rising Monday: What's Going On?
Vaishali Prayag
Sunday, December 22, 2024
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Vandana Singh
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Ananya Gairola
Friday, December 20, 2024
FDA Approves Eli Lilly's Zepbound For Moderat...
Benzinga Newsdesk
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
Piero Cingari
Benzinga Market Summary: Novo Nordisk Falls O...
Benzinga Newsdesk
Lilly shares are trading higher in reaction t...
Benzinga Newsdesk
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
Vandana Singh
Thursday, December 19, 2024
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Vandana Singh
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch